List of GLP-1 receptor agonists: difference between revisions
Diff·revision 19 → 20·23:34, 27 Aug 2025
Difference between revision 19 and revision 20 of List of GLP-1 receptor agonists. 3 lines changed; the page grew by 231 bytes.
| Revision 19 — 05:02, 28 Jul 2025 ListMakerLumi (talk) move the prose introduction above the table 3,631 bytes ±0 | Revision 20 — 23:34, 27 Aug 2025 SeeAlsoSelma (talk) add the column header that was missing 3,862 bytes +231 | ||
|---|---|---|---|
| 45 | Compounds sold under any of these names outside licensed supply are research chemicals, not the approved products, and this wiki does not represent them as suitable for human use. See [[Research use only]].{{r|usp1503}} | 45 | Compounds sold under any of these names outside licensed supply are research chemicals, not the approved products, and this wiki does not represent them as suitable for human use. See [[Research use only]].{{r|usp1503}} |
| 46 | 46 | ||
| + | 47 | Where a compound has no article on this wiki, its name appears here unlinked.{{r|reports}} | |
| + | 48 | ||
| 47 | == References == | 49 | == References == |
| 48 | {{reflist}} | 50 | {{reflist}} |
| ⋮ | ⋮ | ||
| 50 | <ref name="ada2024">American Diabetes Association. "Standards of Care in Diabetes." ''Diabetes Care'' 47(Suppl 1) (2024).</ref> | 52 | <ref name="ada2024">American Diabetes Association. "Standards of Care in Diabetes." ''Diabetes Care'' 47(Suppl 1) (2024).</ref> |
| 51 | <ref name="usp1503">United States Pharmacopeia, General Chapter <1503>, ''Quality Attributes of Synthetic Peptide Drug Substances''.</ref> | 53 | <ref name="usp1503">United States Pharmacopeia, General Chapter <1503>, ''Quality Attributes of Synthetic Peptide Drug Substances''.</ref> |
| + | 54 | <ref name="reports">PeptidePedia Wiki community test-report tally, 2024–2026 (self-reported; see [[Project:Sourcing_guidelines]]).</ref> | |
| 52 | 55 | ||
| 53 | == See also == | 56 | == See also == |